



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Striascan

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IB/0015	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	02/10/2024		SmPC, Labelling and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



R/0012	Renewal of the marketing authorisation.	25/01/2024	11/03/2024		Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Striascan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IB/0011/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>	28/06/2023	n/a		
IA/0010/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p>	06/12/2022	n/a		

IB/0009	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	05/12/2022	07/12/2023	SmPC, Labelling and PL	
IB/0007	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	05/10/2022	n/a		
IB/0008/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	26/09/2022	n/a		
IB/0006	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	26/09/2022	n/a		
IB/0005	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	01/07/2021	08/07/2022	SmPC	Update sections 4.2, 4.4 and 5.1 of the SmPC in order to describe the possibility of quantitative reading in line with current scientific knowledge.
IB/0004	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	03/09/2020	n/a		

IA/0003	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	17/06/2020	n/a		
IA/0002	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	07/02/2020	n/a		
IA/0001	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	28/01/2020	n/a		